Spermosens AB (SPERM.ST)
SEK 0.01
(0.0%)
SEK 0.01
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 230 Thousand SEK | -81.38% |
| 2022 | 1.23 Million SEK | 238.36% |
| 2021 | 365 Thousand SEK | -27.0% |
| 2020 | 500 Thousand SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 52 Thousand SEK | -37.35% |
| 2024 Q3 | 31 Thousand SEK | -40.38% |
| 2024 Q1 | 83 Thousand SEK | -63.91% |
| 2023 Q4 | 230 Thousand SEK | -38.99% |
| 2023 FY | 230 Thousand SEK | -81.38% |
| 2023 Q3 | 377 Thousand SEK | -27.22% |
| 2023 Q2 | 518 Thousand SEK | -22.11% |
| 2023 Q1 | 665 Thousand SEK | -46.15% |
| 2022 Q1 | 1.33 Million SEK | 266.85% |
| 2022 FY | 1.23 Million SEK | 238.36% |
| 2022 Q4 | 1.23 Million SEK | -3.21% |
| 2022 Q3 | 1.27 Million SEK | -2.37% |
| 2022 Q2 | 1.3 Million SEK | -2.39% |
| 2021 Q4 | 365 Thousand SEK | -27.0% |
| 2021 Q1 | 500 Thousand SEK | 0.0% |
| 2021 Q3 | 500 Thousand SEK | 0.0% |
| 2021 Q2 | 500 Thousand SEK | 0.0% |
| 2021 FY | 365 Thousand SEK | -27.0% |
| 2020 Q4 | 500 Thousand SEK | 0.0% |
| 2020 FY | 500 Thousand SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AroCell AB (publ) | - SEK | -Infinity% |
| Devyser Diagnostics AB (publ) | 600 Thousand SEK | 61.667% |
| Immunovia AB (publ) | 1.78 Million SEK | 87.129% |
| Prostatype Genomics AB (publ) | 67 Thousand SEK | -243.284% |
| SenzaGen AB | 1.67 Million SEK | 86.252% |